Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3690

Renal Denervation Market by Product (Symplicity, EnligHTN, Vessix, Paradise and Iberis) and by Technology (Radiofrequency, Ultrasound and Micro-Infusion) - Global Opportunity Analysis and Industry Forecast, 2014-2022

LI_16522
Pages: 110
Sep 2016 | 2037 Views
face gplus_n
Author's : Deepa Tatkare
Tables: 39
Charts: 56
twit_n pr_n

Renal Denervation Industry: Size and Segmentation:

The global renal denervation market size was estimated $197 million in 2015, and is expected to reach $3,153 million by 2022, with a CAGR of 48.5%. Renal denervation is a minimally invasive catheter-based procedure to treat hypertension. The procedure is generally opted in cases where drug therapies are unable to provide relief. It includes ablation of the nerves of renal artery wall by the use of radiofrequency pulses or ultrasound. This reduces sympathetic kidney activity, which further leads to a reduced blood pressure.

Many factors drive the renal denervation market, such as changes in lifestyle that leads to resistant hypertension, increase in prevalence of hypertension, and the technological advancements to develop alternative technologies, such as micro-infusion, for renal denervation systems. However, stringent regulatory norms for renal denervation devices, and unfavorable reimbursements for renal denervation procedure have restricted the market growth.

RENAL DENERVATION MARKET SEGMENTATION
Renal Denervation Market Segmentation

Get more information on this report : Request Sample Pages

Segment Review:

According to the analysis carried out for each segment, the Symplicity Renal Denervation System accounted for the largest market share in 2015. Symplicity is the major and most frequently used product of the renal denervation market. According to the CIRSE Member Survey (2013), Symplicity is used by approximately 78% of the European hospitals. This system is generally preferred as it delivers low level of RF energy and thus reduces the potential risks associated with high levels of RF radiation on body tissues. Above all, the device provides a minimally invasive method to treat excessive hypertension. In addition, the Vessix Renal Denervation System is expected to have the highest growth rate as it uses a full-color graphic user interface that increases the accuracy and operation of the device. This feature enables the Vessix system to be a preferred system by physicians as well as patients.

 

RENAL DENERVATION MARKET, BY PRODUCT, 2015, ($MILLION)

Renal Denervation Market, By Product, 2015

Get more information on this report : Request Sample Pages

Australian Renal Denervation Market Snapshot:

Australia is considered to be a potential market for the growth of renal denervation devices in the coming future. The renal denervation systems, such as Symplicity Renal Denervation System and Vessix Renal Denervation System, have received regulatory approvals from Therapeutic Goods Administration (TGA) in the region and are available for sales. The companies in this market have launched clinical trials in this region to check the effect of devices over patients’ health and test the device efficacy. In this regard, Medtronic launched Symplicity HTN-1, Symplicity HTN-2, and Symplicity-HF trials in Australia as well as some other geographical locations. Moreover, St. Jude Medical, Inc. also launched EnligHTN I, EnligHTN II, and EnligHTN III trials in many regions including Australia. Thus, the leading players are focusing on expansion in the Australian economy, which will lead to market growth in this region.

Australia: Renal Denervation Market, 2014‐2022 ($Million)

Australia: Renal Denervation Market, 2014 - 2022

Get more information on this report : Request Sample Pages

Top Impacting Factors

Prevalence of hypertension

Hypertension is one of the most prevalent diseases in the world. According to the 2012 article of Journal of Hypertension, atrial hypertension affects approximately 25% of the global population. According to the 2011 statistics provided by the American Heart Association, approximately 33% (nearly 70 million people) of the U.S. adult population is suffering from high blood pressure.

Changing lifestyle of people

Major lifestyle changes, such as smoking, alcohol consumption, increased consumption of ready to consume food products, and lack of physical activity of people, increases the chance for hypertension and high blood pressure. Studies have revealed a clear link between the consumption of high levels of salt and rise in blood pressure.  

Improvement of healthcare infrastructure in developing countries

Over the past decade, governments of various countries, especially emerging economies, have increased their expenditure on developing their healthcare infrastructure. According to the World Bank, China increased its healthcare expenditure from 5% in 2011 to 5.5 % of its GDP in 2015. Hence, the increase in investment in the healthcare sector have attracted market players to invest in the market.

Cost effectiveness of the Procedure

According to a 2012 article of Journal of the American College of Cardiology, the catheter-based renal denervation process is a cost-effective procedure to control resistant hypertension. This fact is also supported by a 2014 article of NCBI, which states that renal denervation is a cost-effective alternative when compared to anti-hypertensive pharmacological treatment.

Painful Procedure

Renal denervation is a painful procedure when compared to drug-based therapies for the control of blood pressure. The radiofrequency waves used during the process create ablations in the wall of renal artery. In addition, these waves also heat the arterial tissues and impose harmful effects on the wall of renal artery. These factors may hamper the market growth.

Stringent approval process for renal denervation devices 

The approval processes in most counties are stringent for renal denervation devices, as these are highly specialized devices that are introduced in the body.

TOP IMPACTING FACTORS: RENAL DENERVATION MARKET

Top Impacting Factors: Renal Denervation Market

Get more information on this report : Request Sample Pages

KEY BENEFITS OF RENAL DENERVATION MARKET:

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
  • The report provides a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis by products interprets various types of devices used for renal denervation.
  • Competitive intelligence highlights the business practices followed by leading players across different regions.
  • Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these geographies.
  • Key market players are profiled in the report and their strategies are analyzed thoroughly, which predicts the competitive outlook of the global market.
  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

RENAL DENERVATION MARKET KEY SEGMENTS:

By Product

  • Symplicity Renal Denervation System
  • EnligHTN
  • Vessix Renal Denervation System
  • Paradise Renal Denervation System
  • Iberis Renal Sympathetic Denervation System
  • Others

By Technology

  • Radiofrequency
  • Ultrasound
  • Micro-infusion

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.2.2.1 Competitive intelligence of companies and their strategies

3.3 Porters five forces analysis

3.3.1 Bargaining power of the suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Competitive rivalry
3.3.5 Threat of substitutes

3.4 Market share analysis, 2015
3.5 Market dynamics

3.5.1 Drivers

3.5.1.1 Prevalence of hypertension
3.5.1.2 Changing lifestyle of people
3.5.1.3 Improvement of healthcare infrastructure in developing countries
3.5.1.4 Cost effectiveness of the procedure

3.5.2 Restraints

3.5.2.1 Painful procedure
3.5.2.2 Stringent approval process for renal denervation devices

3.5.3 Opportunities

3.5.3.1 Applications of renal denervation in other diseases
3.5.3.2 Clinical Trials

3.6 Clinical trials

3.6.1 The Symplicity clinical trial program

3.6.1.1 SYMPLICITY HTN-1
3.6.1.2 SYMPLICITY HTN-2
3.6.1.3 SYMPLICITY HTN-3
3.6.1.4 Global SYMPLICITY Registry
3.6.1.5 SYMPLICITY-HF
3.6.1.6 Symplicity Spyral(TM) Catheter Feasibility Study
3.6.1.7 HTN-Japan
3.6.1.8 SYMPLICITY HTN-India

3.6.2 Clinical trials for EnligHTN renal denervation system

3.6.2.1 EnligHTN I Trial
3.6.2.2 EnligHTN II Trial
3.6.2.3 EnligHTN III Trial
3.6.2.4 EnligHTN IV Trial
3.6.2.5 EnligHTNment Trial

3.6.3 Other clinical trials

Chapter: 4 WORLD RENAL DENERVATION MARKET, BY PRODUCT

4.1 Overview

4.1.1 Market size and forecast

4.2 Symplicity

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Vessix (V2)

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 EnligHTN

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Paradise

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast

4.6 Iberis

4.6.1 Key market trends
4.6.2 Key growth factors and opportunities
4.6.3 Market size and forecast

4.7 Others

4.7.1 Key market trends
4.7.2 Key growth factors and opportunities
4.7.3 Market size and forecast

Chapter: 5 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY

5.1 Overview

5.1.1 Market size and forecast

5.2 Radiofrequency

5.2.1 Market size and forecast

5.3 Ultrasound

5.3.1 Market size and forecast

5.4 Micro-infusion

5.4.1 Market size and forecast

Chapter: 6 WORLD RENAL DENERVATION MARKET, BY GEOGRAPHY, 2014-2022

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S. market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico market size and forecast

6.3 Europe

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Germany market size and forecast
6.3.5 France market size and forecast
6.3.6 U.K. market size and forecast
6.3.7 Italy market size and forecast
6.3.8 Spain market size and forecast
6.3.9 Rest of Europe market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan market size and forecast
6.4.5 China market size and forecast
6.4.6 India market size and forecast
6.4.7 Australia market size and forecast
6.4.8 New Zealand market size and forecast
6.4.9 Others market size and forecast

6.5 LAMEA

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Brazil market size and forecast
6.5.5 South Africa market size and forecast
6.5.6 Saudi Arabia market size and forecast
6.5.7 Rest of LAMEA market size and forecast

Chapter: 7 COMPANY PROFILES

7.1 Ablative Solutions, Inc.

7.1.1 Company Overview
7.1.2 Company Snapshot
7.1.3 Operating Business Segments
7.1.4 Key Strategic Moves & Developments

7.2 Boston Scientific Corporation

7.2.1 Company Overview
7.2.2 Operating Business Segments
7.2.3 Business Performance
7.2.4 Key Strategic Moves & Developments

7.3 Cardiosonic Ltd

7.3.1 Company Overview
7.3.2 Company Snapshot
7.3.3 Key Strategic Moves & Developments

7.4 Kona Medical, Inc.

7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Key Strategic Moves & Developments

7.5 Medtronic plc

7.5.1 Company Overview
7.5.2 Company Snapshot
7.5.3 Operating Business Segments
7.5.4 Business Performance
7.5.5 Key Strategic Moves & Developments

7.6 Mercator MedSystems, Inc.

7.6.1 Company Overview
7.6.2 Company Snapshot
7.6.3 Operating Business Segments
7.6.4 Key Strategic Moves & Developments

7.7 ReCor Medical, Inc.

7.7.1 Company Overview
7.7.2 Company Snapshot
7.7.3 Key Strategic Moves & Developments

7.8 Renal Dynamics Limited

7.8.1 Company Overview
7.8.2 Company Snapshot
7.8.3 Key Strategic Moves & Developments

7.9 St. Jude Medical, Inc.

7.9.1 Company Overview
7.9.2 Operating Business Segments
7.9.3 Business Performance
7.9.4 Key Strategic Moves & Developments

7.10 Terumo Corporation

7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating Business Segments
7.10.4 Business Performance
7.10.5 Key Strategic Moves & Developments

List of Charts

FIG. 1 WORLD RENAL DENERVATION MARKET, BY PRODUCT, 2015 VS 2022, ($MILLION)
FIG. 2 RENAL DENERVATION MARKET SEGMENTATION
FIG. 3 TOP INVESTMENT POCKETS IN THE WORLD RENAL DENERVATION MARKET
FIG. 4 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIG. 5 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 6 TOP COMPANIES AND THEIR STRATEGIES
FIG. 7 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 9 PORTERS FIVE FORCES ANALYSIS
FIG. 10 MARKET SHARE ANALYSIS, 2015
FIG. 11 TOP IMPACTING FACTORS: RENAL DENERVATION MARKET
FIG. 12 MAIN FACTORS THAT CONTRIBUTE TO THE DEVELOPMENT OF HIGH BLOOD PRESSURE AND ITS COMPLICATIONS
FIG. 13 HYPERTENSION CONTROL IN PATIENTS TREATED BY MULTIDRUG APPROACH, (% OF PATIENTS)
FIG. 14 WORLDWIDE HYPERTENSION POPULATION
FIG. 15 MAJOR CLINICAL TRIALS IN RENAL DENERVATION MARKET
FIG. 16 EUROPE CLINICAL TRIALS, (%)
FIG. 17 ASIA-PACIFIC CLINICAL TRIALS, (%)
FIG. 18 NORTH AMERICA CLINICAL TRIALS, (%)
FIG. 19 LAMEA CLINICAL TRIALS, (%)
FIG. 20 PIPELINE PRODUCTS IN RENAL DENERVATION MARKET
FIG. 21 PREVALENCE OF RESISTANT HYPERTENSION IN NORTH AMERICA (%)
FIG. 22 U.S.: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 23 CANADA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 24 MEXICO: COSMETIC IMPLANTS MARKET, 20142022 ($MILLION)
FIG. 25 PREVALENCE OF RESISTANT HYPERTENSION IN EUROPE (%)
FIG. 26 GERMANY: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 27 FRANCE: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 28 UK: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 29 ITALY: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 30 SPAIN: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 31 REST OF EUROPE: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 32 PREVALENCE OF RESISTANT HYPERTENSION IN ASIA-PACIFIC (%)
FIG. 33 JAPAN: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 34 CHINA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 35 INDIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 36 AUSTRALIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 37 NEW ZEALAND: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 38 OTHERS ASIA-PACIFIC: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 39 PREVALENCE OF RESISTANT HYPERTENSION IN LAMEA (%)
FIG. 40 BRAZIL: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 41 SOUTH AFRICA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 42 SAUDI ARABIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 43 REST OF LAMEA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 44 BOSTON SCIENTIFIC: NET SALES, 20132015 ($MILLION)
FIG. 45 BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2015 (%)
FIG. 46 BOSTON SCIENTIFIC: NET SALES, BY GEOGRAPHY, 2015 (%)
FIG. 47 MEDTRONIC: NET SALES, 20142016 ($MILLION)
FIG. 48 MEDTRONIC: NET SALES, BY SEGMENT, 2016 (%)
FIG. 49 MEDTRONIC: NET SALES, BY GEOGRAPHY, 2016 (%)
FIG. 50 MEDTRONIC: STRATEGY SHARE, 20132014 (%)
FIG. 51 ST. JUDE MEDICAL: NET SALES, 20132015 ($MILLION)
FIG. 52 ST. JUDE MEDICAL: NET SALES, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 53 ST. JUDE MEDICAL: NET SALES, BY GEOGRAPHY, 2015 (%)
FIG. 54 TERUMO: NET SALES, 20142016 ($MILLION)
FIG. 55 TERUMO: NET SALES, BY SEGMENT, 2016 (%)
FIG. 56 TERUMO: NET SALES, BY GEOGRAPHY, 2016 (%)

List of Tables

TABLE 1 OTHER CLINICAL TRIALS
TABLE 2 WORLD RENAL DENERVATION MARKET, BY TYPE, 20142022 ($MILLION)
TABLE 3 SYMPLICITY RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 4 VESSIX RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 5 ENLIGHTN RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 6 PARADISE RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 7 IBERIS RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 8 OTHER RENAL DENERVATION SYSTEMS MARKET, BY REGION, 20142022 ($MILLION)
TABLE 9 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 10 RADIOFREQUENCY RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 11 ULTRASOUND RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 12 MICRO-INFUSION RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 13 RENAL DENERVATION MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
TABLE 14 NORTH AMERICA: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 15 NORTH AMERICA: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 16 NORTH AMERICA: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 17 EUROPE: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 18 EUROPE: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 19 EUROPE: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 20 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 21 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 22 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 23 LAMEA: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 24 LAMEA: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 25 LAMEA: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 26 ABLATIVE SOLUTIONS: COMPANY SNAPSHOT
TABLE 27 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 28 BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 29 CARDIOSONIC: COMPANY SNAPSHOT
TABLE 30 KONA MEDICAL: COMPANY SNAPSHOT
TABLE 31 MEDTRONIC: COMPANY SNAPSHOT
TABLE 32 MEDTRONIC: OPERATING SEGMENTS
TABLE 33 MERCATOR: COMPANY SNAPSHOT
TABLE 34 RECOR MEDICAL: COMPANY SNAPSHOT
TABLE 35 RENAL DYNAMICS - COMPANY SNAPSHOT
TABLE 36 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 37 ST. JUDE MEDICAL: PRODUCT CATEGORIES
TABLE 38 TERUMO: COMPANY SNAPSHOT
TABLE 39 TERUMO: OPERATING SEGMENTS

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Renal Denervation Market- Global Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $3690
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4099
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $4999
  • Restricted to one authorized users
  • One print only
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6004
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8373
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo